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ABSTRACT 
 
 
 
Atherogenesis is equally influenced by dyslipidemia and inflammation, and both innate 
and adaptive immune responses have been shown to modulate atherosclerotic lesion 
formation. In fact immune mechanisms may even be decisive in the clinical outcome. The 
immune responses involved are prominently directed against oxidation-specific epitopes 
on oxidized low-density lipoproteins (OxLDL) as well as on apoptotic cells, which are both 
present in atherosclerotic lesions. Oxidation-specific epitopes are generated as a 
consequence of lipid peroxidation, and represent danger signals that are recognized by 
IgM natural antibodies (NAbs), which are produced by innate B1 cells, in humans and 
mice. The exact role of B cell populations in atherogenesis is still unclear, though it has 
been shown that B cell depletion by CD20 antibody treatment, which severely depletes 
B2 cells and dramatically reduces IgG antibodies  but affects B1 cells and IgM antibodies to 
a lesser extent, significantly reduces lesion formation. Mice deficient in serum IgM 
antibodies, which lack NAbs, have significantly accelerated lesion formation, and we 
hypothesize that B1 cells and the natural antibodies they secrete protect from 
atherosclerosis, whereas the adaptive humoral immunity mediated through B2 cells and 
IgG antibodies act pro-atherogenic. Indeed, in a recent publication Kyaw et al. showed 
that the B1a lymphocyte subpopulation is atheroprotective, as the phenotype of 
aggravated lesion formation in splenectomized ApoE deficient mice was reversed by  
adoptive transfer of B1a cells. The possibility to study the role of the entire B1 cell pool 
could be achieved by specific depletion of B2 cells with neutralizing antibodies that are 
directed against the BAFF-BAFFR interaction. BAFF-BAFFR interaction is crucial for the 
survival of B2 cells, while BAFF inhibition in vivo leaves natural antibody producing B1 
cells unaffected. In this thesis I primarily focused on the function of the BAFFR on B1 cells 
and could indicate a role of the BAFF-BAFFR interaction with respect to spontaneous IgM 
secretion. I could show that neutralization of BAFF signaling leads to increased production 
of IgM antibodies by B1 cells. In addition, I could show that macrophages stimulate IgM 
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secretion of B1 cells and that this stimulation is dependent on cell contact. In this regard, I 
observed the hitherto unknown fact that macrophages express the BAFFR. 
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ZUSAMMENFASSUNG 
 
 
 
Atherosklerose wird sowohl von Fettstoffwechselstörungen als auch durch Entzündung 
beeinflusst. Dabei wird die Bildung von Läsionen durch  angeborene und adaptive 
Immunmechnanismen moduliert. Diese Immunantwort richtet sich in erster Linie gegen 
oxidationsspezifische Epitope auf oxidierten Lipoproteinen niedriger Dichte (LDL) und 
apoptotischen Zellen, die in atherosklerotischen Läsionen akkumulieren. 
Oxidationsspezifische Epitope werden durch Lipidperoxidation gebildet und sind 
Gefahrensignale, die sowohl im Menschen als auch in Tieren durch natürliche IgM 
Antikörper, welche von angeborenen B1 Zellen stammen, erkannt werden. Die genaue 
Rolle von B Zellen und deren Subpopulationen in der Atherogenese ist nachwievor unklar. 
Vor kurzem wurde jedoch gezeigt, dass die Depletion von B Zellen durch einen CD20 
Antikörper, der vorzugsweise B2 Zellen und deren IgG Antikörper  jedochnicht B1 Zellen 
und IgM Antikörperreduziert, die Entstehung von Läsionen drastisch mindert. Auf der 
anderen Seite weisen Mäuse, die keine Serum IgM Antikörper besitzen, auch verstärkte 
Läsionsbildung auf. Wir vermuten daher, dass B1 Zellen und die natürlichen Antikörper, 
die sie freisetzen vor Atherosklerose schützen, während die adaptive Immunabwehr, die 
von B2 Zellen und ihren IgG Antikörpern übermittelt wird, proatherogen wirkt. Erst 
kürzlich zeigte eine Publikation, dass B1a Zellen tatsächlich atheroprotektiv wirken, da der 
Phenotyp von ApoE-/- Mäusen, die nach Entfernung der Milz verstärkt atherosklerotische 
Läsionen bilden, durch adoptiven Transfer von B1a Zellen gerettet werden konnte. Die 
Möglichkeit den gesamten B1 Zellpool zu untersuchen wäre durch spezifische Elimination 
von B2 Zellen gegeben und könnte durch Verwendung eines neutralisierenden 
Antikörpers, der gegen die BAFF-BAFFR Interaktion gerichtet ist erreicht werden. BAFF-
BAFFR Interaktion ist unentbehrlich für das Überleben von B2 Zellen, während BAFF 
Hemmung in vivo natürliche Antikörper produzierende B1 Zellen unberührt lässt. Diese 
Diplomarbeit beschäftigt sich primär mit der Funktion des BAFFR auf B1 Zellen und zeigt, 
dass BAFF-BAFFR Interaktion eine Rolle bei der spontanen IgM Sekretion spielt. Ich 
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konnte beobachten, dass die Neutralisation des BAFF-Signalweges zu einer erhöhten 
Produktion von IgM Antikörpern durch B1 Zellen führt. Außerdem konnte ich zeigen, dass 
Makrophagen die IgM Sekretion von B1 Zellen stimulieren und diese Stimulation direkten 
Zellkontakt erfordert. Zusätzlich konnte ich bisher noch unbeschriebene BAFFR-
Expression auf Makrophagen aufdecken. 
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INTRODUCTION 
 
 
 
ATHEROSCLEROSIS 
 
Atherosclerosis is a chronic inflammatory disorder of large and medium-sized arteries. It 
is the underlying pathological process of myocardial infarctions and a majority of strokes  
and the leading cause of death in the world. In atherogenesis many genetic and 
environmental risk factors, such as hypercholesterolemia, hypertension, diabetes, and 
smoking, have been identified.(1-3) 
The term arteriosclerosis was first introduced by Jean Lobstein in 1829. While for many  
years it was believed that atherosclerosis develops only  through passive accumulation of 
cholesterol in the vessel wall, it is now well established that both dyslipidemia as well as 
inflammatory response influence this complex disease process. This is best documented 
by the fact that increased serum levels of the inflammation marker C-reactive protein 
have been found to be powerful and independent risk factors for future cardiovascular 
disease. Moreover, both the innate and the adaptive immune system have been 
demonstrated to modulate the initiation and progress ion of atherosclerotic lesions. (4-6) 
 
 
Atherosclerotic lesion formation: 
 
High circulating levels of cholesterol still represent the most important risk factor for 
atherogenesis. In the blood a majority of cholesterol is transported by low density 
lipoproteins (LDL), which are surrounded by a shell of phospholipids, free cholesterol and 
apolipoprotein B100 (ApoB100). When circulating LDL accumulates in the intima of the 
artery wall, ApoB100 can bind to proteoglycans on the extracellular matrix. (7) In the 
artery wall retained LDL particles undergo various modifications including oxidation, 
resulting in the release of bioactive lipids and the generation of oxidized LDL (OxLDL). The 
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extent of modification can be minimal, after which the LDL particle can still be bound by 
the LDL receptors, or massive, in which the particles are not recognized by the LDL 
receptor but by scavenger receptors (SR) of macrophages and smooth muscle cells. (8) 
OxLDL carries multiple neo-epitopes that constitute “danger signals” of innate immunity. 
Various components of innate immunity, including IgM natural antibodies (NAbs, see 
subsequently), are directed against these danger signals that are also present on 
apoptotic cells. (9-11)  
 
 
Fig. 1: Stages in the development of atherosclerotic lesions in animal models. (12) 
 
In the initial phase of fatty streak formation a series of stimuli, such as high cholesterol, 
high blood pressure, or pro-inflammatory mediators activate endothelial cells (EC), which 
under normal conditions resist the attachment of white blood cells. In turn, EC express 
adhesion molecules, such as endothelial-cell selectin (E-selectin) and vascular cell 
adhesion molecule 1 (VCAM-1), and chemokines which mediate the recruitment of  
monocytes and T cells to the intima. (7, 13) This is a rate limiting step in atherogenesis, as 
Apo-E-deficient mice (ApoE-/-) lacking both E-selectin and platelet selectin (P-selectin) 
develop less atherosclerosis. (14) 
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When ECs get activated by OxLDL they also produce macrophage colony-stimulating 
factor (M-CSF), which stimulates the proliferation of smooth muscle cells and promotes 
the differentiation of monocytes into macrophages in the intima. (15, 16) Macrophages 
then up-regulate their scavenger receptors that are involved in the uptake and clearance 
of modified LDL particles as well as apoptotic cells. (17) This leads to a massive 
intracellular accumulation of cholesterol esters resulting in the formation of foam cells - 
hallmark cells of early and late atherosclerotic lesions. (18) This is another key event in 
atherogenesis, as mice with a mutation in the M-CSF gene, and therefore a nearly 
complete absence of macrophages, do not develop atherosclerosis when bred to ApoE-/-, 
even though they have elevated circulating cholesterol levels. (16)  
The progression to more complex lesions is characterized by immigration of SMC from the 
medial layer of the artery wall into the subendothelial space. They then proliferate and 
can also take up modified lipoproteins, further contributing to foam cell formation. 
Moreover, SMCs synthesize extracellular matrix proteins, including interstitial collagen 
and elastin that promote the development of the fibrous cap, which covers the plaque. 
(19) Underneath this cap macrophage-derived foam cells accumulate and undergo 
apoptosis. Inefficient clearance of dead cells leads to the formation of a lipid-rich acellular 
core, the so called necrotic core. Degradation and subsequent rupture of the cap releases 
the pro-thrombotic material from the plaque into the blood and causes thrombus 
formation and thrombotic occlusion of the artery. (20) (Fig. 1) 
 
The role of DCs in atherogenesis might be antigen presentation of modified LDL 
components in regional lymph nodes. DCs already reside in the artery wall before 
atherosclerosis development and are thought to promote tolerization to antigens by 
silencing T cells, but during atherogenesis accumulating danger signals may activate DCs 
to switch to the activation of adaptive immunity. (18, 21-23)  
The impact of T cells on atherosclerosis has been addressed in several studies; they are 
recruited through similar mechanisms as macrophages, involving adhesion molecules and 
chemokines. T cells are traditionally divided into Th1 cells, responsible for cell-mediated 
immunity and secreting IFN-γ and IL-2, and Th2 cells, which secrete IL-4, IL-5, IL-10, IL-13, 
and provide help for antibody production by B cells. Th1 produce proatherogenic 
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mediators and contribute to lesion growth and disease aggravation. Regulatory T cells 
(Treg) inhibit this process. (18, 24, 25) 
B cells and the antibodies they secrete do not appear to be required for the development 
of atherosclerosis but play an important modulatory role, which is discussed in more 
detail subsequently. 
 
 
 
NATURAL ANTIBODIES AND OXIDATION-SPECIFIC EPITOPES: 
 
NAbs are produced very early in life by a specialized subset of B cells, named B1 cells in 
mice. They are defined as pre-existing antibodies carrying germ line or close to germ line 
encoded variable regions and are termed natural because they arise spontaneously 
without antigen exposure. Most NAbs are of the IgM, but to some extent also of the IgG 
and IgA isotype. (26-29)  
The NAb repertoire is thought to be a product of natural selection and has broad 
specificity for phylogenetically conserved structures of nucleic acids, (glyco)proteins and 
(phospho)lipids. Numerous foreign and altered self antigens contain those structures and 
therefore NAbs are involved in the first line defence against invading pathogens. 
Moreover they recognize altered or stress-induced neo-self-structures on damaged 
molecules and cellular debris and therefore mediate tissue homeostasis. (26, 27) 
 
Typical examples of stress-induced antigens are lipid-peroxidation derived oxidation-
specific epitopes. (11) OxLDL, which carries oxidation-specific epitopes, is a highly 
abundant antigen in atherosclerotic lesions. (30) Recently, it has been shown that 
oxidation-specific epitopes are targets of NAbs in mice and humans. (31) 
Phosphatidylcholine is the major phospholipid of LDL. Peroxidation of  
phosphatidylcholine leads to the formation of highly reactive breakdown products, such 
as malondialdehyde (MDA) type adducts, 4-hydroxynonenal (4-HNE), and 1-palmitoyl-2-
(5-oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC). (32) IgM and IgG autoantibodies 
against model epitopes of Ox-LDL, such as Cu2+-oxidized LDL (CuOx-LDL) and MDA-
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modified LDL (MDA-LDL), have been documented in the sera and atherosclerotic lesions 
of animal models and humans. (33, 34) Moreover, hypercholesterolemic rabbits and mice 
that were actively immunized with homologous CuOx-LDL or MDA-LDL showed robust IgG 
and IgM responses against the respective antigens and resulted in reduced lesion 
formation. (35-39)  
IgM titers were found to inversely correlate with markers of cardiovascular disease, which 
suggests that IgM antibodies against epitopes of OxLDL protect from cardiovascular 
disease in humans. The lowest levels of anti-OxLDL IgM antibodies have been found in 
patients with the highest risk of developing coronary stenosis and carotid atherosclerosis , 
respectively. (40, 41) 
 
ApoE-/- mice showed to have very high titers of autoantibodies to epitopes of Ox-LDL. The 
spleen of those mice was used to generate a set of hybridomas producing IgM antibodies 
against Ox-LDL. (34) Most of the selected clones bound to either CuOx-LDL or MDA-LDL. 
One example, the EO6 monoclonal anti-OxPL IgM antibody was found to be structurally 
and functionally identical to classical natural T15 anti-PC antibodies produced by B1 and 
marginal zone B cells. (40, 42) Importantly, in terms of atherosclerosis the prototypic anti-
Ox-LDL natural IgM antibody T15/EO6 has been shown to reduce lesion formation. (43) 
Recently, the protective effect of natural IgM Abs was demonstrated by Lewis et al. The 
authors reported that low-density lipoprotein receptor deficient (LDLR-/-) mice also 
deficient in serum IgM antibodies (sIgM-/-), and therefore lack NAbs, develop greatly 
accelerated atherosclerosis in both the aortic root and the entire aorta. (44) 
Several explanations for the protective effects of natural IgM in atherosclerosis can be 
offered: Studies in sIgM-/- mice have shown that NAbs promote the clearance of apoptotic 
cells. For example, both the OxLDL-specific IgM T15/EO6 and MDA-LDL specific IgM NA17 
was able to promote the clearance of apoptotic cells in mice in vivo. (45-47) In addition, 
NAbs have been shown to protect from autoimmunity – in part by promoting apoptotic 
cell clearance. Autoimmunity and defective apoptotic cell clearance predispose to 
increased atherosclerosis, thus the cell clearance property of NAbs may indicate an 
important atheroprotective function of NAbs. 
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Furthermore, NAbs have been shown to regulate B cell maturation, maintenance and 
survival as they can present self antigens to immature B cells. The fact, that in both young 
and adult sIgM-/- mice B1 cells as well as marginal zone B (MZB)-cells are strongly 
increased, and B2 cell responses are impaired, illustrates important regulatory functions 
of natural IgM antibodies. (48-50)  
Additionally, B cell receptor (BCR) signaling, which is required for splenic B2 cell selection 
is also promoted by natural IgM antibodies. Absence or low titers of natural IgM 
potentially lead to insufficient BCR signaling and autoreactive B cells potentially escape 
deletion by apoptosis. (51, 52) Eventually, due to their binding properties to altered self 
structures, NAbs have been demonstrated to play a role in tumor immunosurveillance 
and neurodegenerative disorders such as Alzheimer’s disease. (53-55)  
 
 
 
B CELL SUBPOPULATIONS IN ATHEROSCLEROSIS: 
 
During embryonic life B lymphocytes develop in the fetal liver and later on are generated 
in the bone marrow from hematopoietic stem cells. (56) The maturation process of B cells 
is divided into different developmental stages that are characterized by the expression of 
various microRNAs and cell surface markers and the rearrangement of IgH and IgL. (57-
59) Following the commitment of the cells to the B cell lineage, they first pass through the 
pro-B stage, where signaling through interleukin-7 (IL-7) receptor is essential and there is 
partial rearrangement of IgH. At the pre-B-cell stage, IgH recombination is complete, the 
cells express a pre-BCR, and IgL chain gene rearrangement begins. (58) The immature B-
cell stage is determined by the expression of a mature BCR after successful IgL 
rearrangements. At this point, immature B cells exit the bone marrow to join the 
transitional compartment in the spleen (T1 and T2), prior to mature B cells. (60, 61)  
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Fig. 2: Stages in B cell maturation. (62) 
 
There are two different subsets of B cells, termed B1 and B2 cells  that differ in their 
surface marker expression, activation requirements and anatomical localization. (63) The 
B2 lineage includes follicular, germinal center, and plasma B cells. Germinal center 
formation can occur in the spleen, lymph nodes, or mucosa associated lymphoid tissue 
and leads to memory and plasma cells . The latter cells can be found in the bone marrow, 
peripheral tissues, and the spleen. (62) (Fig. 2) 
B1 cells are the main population in the peritoneal and pleural cavities in mice, but are 
rare in lymph nodes and have a self-replenishing capacity. (64) The development of B1 
cells occurs generally during fetal or perinatal life. There are two different paradigms for 
the ontogeny of B1 cells. One proposes distinct progenitors for B1 and B2 cells, while the 
other one suggests their development from a common progenitor, where antigenic 
selection at the sIgM+ stage decides which way the cell pursues. (65-70)  
 
B cells rarely appear within atherosclerotic plaques, but have been described to be part of 
tertiary lymphoid organs in the adventitial areas close to plaques. In addition to central 
and other peripheral lymphoid organs, these B- and T cell clusters may also be sites of 
antibody production during atherogenesis. (71, 72) 
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Various studies in atherosclerosis-prone mice provided insights into the important role of 
lymphocytes in influencing the atherogenic disease process. (73) Studies in LDLR-/- or 
ApoE-/- deficient mice that were crossed with mice deficient in recombinase activating 
gene 1 or 2 (Rag1-/- or Rag2-/-) showed an overall pro-atherogenic activity of lymphocytes. 
These functionally T and B cell deficient mice were found to have less severe plaque 
formation than immunocompetent LDLR-/- and ApoE-/- mice. However, the fact that these 
mice still develop atherosclerosis led to the assumption that lymphocytes are not 
necessary for the initiation of atherosclerotic lesion formation. Indeed, in extremely 
hypercholesterolemic mice, no differences regarding atherosclerosis between Rag 
deficient and immunocompetent mice could be observed. (74, 75) These data 
demonstrate that lymphocytes are not required for atherogenesis, but they have the 
ability to profoundly modulate lesion formation. 
The active participation of B cells in murine atherosclerosis could be shown by studies in 
ApoE-/-, which showed aggravated atherosclerosis and reduction of anti-Ox-LDL 
antibodies, upon splenectomy. Transfusion of splenic B cells, but not T cells, from 
atherosclerosis-prone ApoE-/- mice into young ApoE-/- mice, and thereby reconstitution of 
IgM antibodies to Ox-LDL epitopes, resulted in reduced atherosclerosis. (76) Moreover, 
the consequence of B-cell deficiency was directly tested in lethally irradiated LDLR-/- mice 
that were reconstituted with bone marrow from µMT mice that lack B cells. The result 
showed up to 40% increased lesion size accompanied by decreased production of anti -
oxLDL antibodies in B-ell deficient mice. (77)  
Regarding these studies an overall atheroprotective role for B cells could be suggested, 
which might be explained by their capacity to secrete protective antibodies and/or to 
mediate direct immunoregulatory functions. Surprisingly, two different studies in ApoE-/- 
and LDLR-/- mice that applied CD20 antibody treatment to deplete B cel ls, showed 
significantly reduced lesion formation after the treatment. (78, 79) This could be 
explained by opposing activities of the two major B cell subsets. CD20 Ab treatment 
showed drastically reduced total IgG and OxLDL-specific IgG titers, whereas the IgM titers 
against OxLDL were less affected (30% reduction) or even preserved. (79) Consistent with 
this, natural IgM producing B1 cells in the peritoneum were depleted to a lesser extent 
than conventional B2 cells, which is consistent with the fact that the peritoneal cavity 
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represents a protective niche for B1 cells during anti-CD20 treatment. These data 
suggested a possible pro-atherogenic function of B2 but not B1 cells. Adoptive transfer of 
splenic B2 cells into total lymphocyte (TKO) or B-cell deficient (µMT ko) Apoe-/- mice 
indeed resulted in increased atherosclerosis, while adoptive transfer of splenic B1 cells 
had no effect. (80) Additionally, Kyaw et al. described the B1a subpopulation as  
atheroprotective in a very recent publication. Removal of the spleen in Apoe-/- mice 
reduces the peritoneal B1a cell pool and leads to decreased serum IgM titers, while the 
mice show promoted lesion formation. Adoptive transfer of B1a cells  rescues this 
phenotype and reduces atherosclerosis progression. (81) 
 
Based on these findings, we hypothesize that B cell subpopulations may have contrasting 
roles in atherosclerosis. B1 cells and the natural antibodies they secrete protect from 
atherosclerosis, whereas the adaptive humoral immunity mediated through B2 cells and 
IgG antibodies promote atherogenesis. (78)  
A selective depletion of B2 cells by antibodies in an atherosclerosis context has not been 
the focus of research yet. Neutralizing antibodies, which are directed against the signal 
molecule B-cell activating fundamental factor (BAFF/BlyS) or one of its receptors (BAFFR) 
provide the opportunity to obtain the above mentioned effect, which is to achieve B2 cell 
depletion while preserving the B1 cell-pool in mice. In this context it has already been 
shown that BAFF-deficient mice have intact B1 cell numbers, whereas the B2 cell numbers 
are drastically reduced. Additionally, it was shown that BAFF inhibition in vivo leaves 
natural antibody producing cells unaffected. (82, 83) 
 
 
 
B-CELL ACTIVATING FACTOR SIGNALING: 
BAFF and APRIL 
 
B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are tumor 
necrosis factor (TNF) family members. They are mainly produced by innate immune cells 
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such as neutrophils, macrophages, monocytes, DCs and follicular DCs (FDCs)  and are 
crucial for peripheral B cell survival. Type I interferons (IFNs), IFN , IL-10 and granulocyte 
colony-stimulating factor (G-CSF), as well as the activation of Toll-like receptors, such as 
TLR4 and TLR9, increase the expression of these two ligands. (62, 84, 85) Moreover, T 
cells, activated B cells and B cell chronic lymphocytic leukemia (BCLL) cells can also 
produce the homotrimeric type II transmembrane proteins BAFF and APRIL. (85) 
BAFF is initially synthesized as cell-bound protein and following activation of the cell 
proteolytically cleaved at furin consensus sequences yielding a soluble cytokine. While 
APRIL does not exist in a membrane bound form, as the biologically active protein is 
directly secreted after intracellular processing in the Golgi , BAFF also appears membrane 
bound. (86, 87) Released BAFF usually forms trimers, but it can also further assemble to 
BAFF 60-mers, with still accessible receptor binding sites. (88) Furthermore, BAFF and 
APRIL can form heteromers. (87) 
 
 
Receptors 
 
Common receptors for BAFF and APRIL are B cell maturation antigen (BCMA, TNFRSF17) 
and transmembrane activator and calcium modulator and cyclophilin ligand interactor 
(TACI, TNFRSF13B), but BAFF also binds to the BAFF receptor (BAFFR, BR3, TNFRSF13C). 
(87, 89) 
The receptors are mainly expressed by B cells. (90, 91) The expression of BAFFR is low on 
newly formed immature murine B cells, but increases as these cells  evolve and is 
ultimately expressed by all mature B cells. (90) Furthermore, the BAFFR is also expressed 
by regulatory T cells. (92) TACI is produced by all peripheral B cells, marginal zone B cells 
and B1 B cells. (93) Signaling through TACI and BAFFR have opposite roles. While BAFFR 
transmits survival signals and positively regulates B-cell homeostasis, signaling through 
TACI reduces B cell numbers. (93, 94) 
 
When BAFF ligand binds to the BAFFR, at least a trimer has to bind to initiate signalling, as 
three independent receptors need to be bound by the ligands to arrange in close 
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proximity for signal transmission. For signalling through TACI binding of BAFF 60-mers are 
necessary. (88) 
TNF receptor-associated factors (TRAFs) are trimeric intracellular proteins that bind linear 
TRAF-binding sequences present in several receptors including the BAFFR. The affinity of 
TRAFs for monomeric receptor peptides is low, but ligand-induced oligomerization 
stabilizes the interaction. (95) BAFFR recruits exclusively TRAF3, which usually interacts 
with NF-κB-inducing kinase (NIK), the upstream kinase responsible for NF-κB2 processing. 
Together with TRAF2 it induces NIK degradation by the proteasome; thus preventing the 
activation of the alternative NF-κB pathway. When BAFF is bound to the BAFFR, TRAF3 is 
recruited and degraded in a TRAF2-dependent manner, resulting in the stabilization of 
NIK and activation of NF-κB2, which then promotes B cell survival. (59, 96-98) (Fig. 3) 
 
 
Fig. 3: BAFF-BAFFR signaling. (85) 
 
The expression of a functional BCR is one essential event for early B cell development and 
later peripheral B cell homeostasis. However, BAFF plays an additional factor in the 
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persistence of peripheral B cells. The first indication that BAFF may be a survival factor 
came from the expanded peripheral B cell numbers and elevated serum Ig levels, found in 
mice over expressing BAFF. (59, 99, 100) 
 
Studies in mice have shown that BAFF is not playing a critical role in B cell development in 
the bone marrow. Moreover the survival of immature or splenic T1 cells is not dependent 
on BAFF signaling. (61, 83, 101, 102) Nevertheless, a fundamental role for BAFF in the 
survival of splenic T2 B cells, and mature and marginal zone (MZ) B cells could be 
indicated. This was supported by analysis of BAFF-treated and BAFF-transgenic mice, 
which showed normal bone marrow and T1 compartments, but expanded T2 and MZ 
populations. (103, 104) In contrast, BAFF or APRIL are not necessary for the survival of B1 
B cells, memory B cells and a small population of mature splenic B cells. (102, 105, 106) 
Sasaki et al. generated mice deficient in the BAFFR that showed a similar phenotype as 
BAFF deficient mice: B cells were found to have a developmental block at the transitional 
stage T1 to T2, and a 40-fold reduction in numbers of mature B2 cells with very few - if 
any - MZ B cells, while the B1 compartments stayed unaffected. Whether BAFF is also 
crucial for the survival of mature B cells in vivo was addressed by Rauch et al. when they 
generated an anti-BAFF-R monoclonal antibody and studied its effect in mice. Injections 
of a blocking anti-BAFF-R antibody led to dramatic depletion of the mature B cell 
compartment, and showed that almost all follicular and half of the marginal zone B cells 
are dependent on BAFF-BAFFR signalling. (102, 107)  
 
A correlation between excess BAFF and autoimmunity could be shown in the BAFF-
transgenic mouse. This mouse further demonstrated the first animal model of T cell -
independent lupus. (108) Elevated BAFF levels also have been found in sera of patients 
with various autoimmune conditions. (109) Moreover, BAFF expression has been 
detected in non-lymphoid breast cancer cells from epithelial origin and increased levels of 
BAFF have been shown during inflammation, allergy and viral infection, possibly as a 
consequence of type I IFNs production, which are known to promote BAFF production. 
(85, 110) The fact that increased BAFF serum levels have been found in different diseases 
triggered the development of BAFF an APRIL antagonists. Human Genome Sciences (HGS) 
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and GlaxoSmithKline (GSK) developed a fully human BAFF-specific monoclonal antibody 
(Belimumab) that has been tested successfully in clinical trials. It has been approved by 
the Food and Drug Administration (FDA) in March 2011, for the treatment of adult 
patients with active, autoantibody-positive systemic lupus erythematosus (SLE). 
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AIM OF THESIS 
 
 
 
Selective depletion of B2 cells while preserving the B1 cell pool in atherosclerotic mouse 
models would be an ideal way to strengthen the hypothesis that B1 cells and the natural 
antibodies they produce protect from atherosclerosis, whereas the adaptive humoral 
immunity mediated through B2 cells and IgG antibodies promote atherogenes is. (78) For 
this purpose we believe that neutralizing antibodies, which are directed against the signal 
molecule B-cell activating fundamental factor (BAFF/BlyS) or one of its receptors (BAFFR) 
provide the opportunity to obtain the above mentioned effect. It has been described that 
B2 cell survival is dependent on BAFF-BAFFR signaling, while for B1 cells it is not a 
determinant for survival. In this context it was shown already that BAFF-deficient mice 
have intact B1 cell numbers, whereas the B2 cell numbers are drastically reduced. (83) 
Rauch et al. showed that injection of a blocking anti-BAFFR mAb (9B9 Hybridoma) that 
prevents BAFF from binding showed drastically decreased follicular and marginal zone B 
cell numbers after 2 weeks, whereas B1 cells were not affected. This study established a 
central role for BAFF-BAFFR signaling in the in vivo survival of both follicular and marginal 
zone B cell pools. Moreover using this antibody they showed BAFFR expression on all 
mature B cells, namely B2, MZB, B1 (B1a and B1b) as well as on the three immature 
transitional splenic B cell subsets. (102) 
 
The central experimental aim of this thesis is to understand the importance of BAFF 
signaling through BAFFR in B1 cells with respect to the production of atheroprotective 
NAbs. Using a blocking antibody for BAFFR, I addressed the role of the BAFF-BAFFR 
interaction on B1 cells in vitro with respect to their capacity to secrete natural IgM 
antibodies.  
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RESULTS 
 
 
 
BAFFR blocking in total peritoneal cells: 
 
The highest number of B1 cells can be found in the peritoneal cavity. Thus, I first 
investigated a possible effect of BAFF-BAFFR interaction blockage by examining the role 
of the receptor in total peritoneal cells. I first tested whether blocking the receptor with 
anti-BAFFR antibody, which was kindly provided by Dr. Rolink (University of Basel) (102), 
can influence spontaneous IgM secretion. 
 
Total peritoneal cells were isolated from C57BL/6 mice by peritoneal lavage, cultured in 
vitro, and supernatants were analyzed for IgM secretion.  I compared IgM secretion of 
these cells over 48h under three different conditions: 1) cells left untreated; 2) cells 
treated with the anti-BAFFR blocking antibody; and 3) cells in presence of an isotype 
matched IgG2b control antibody. IgM antibody concentrations in the supernatants were 
measured by a sandwich ELISA. The results of this measurement (Fig.4-a) showed that 
IgM concentrations are increased when cells are incubated in presence of anti-BAFFR 
compared to untreated peritoneal cells and those treated with the isotype control. 
Moreover, the increased IgM secretion in the aBAFFR treated cells was dose-dependent, 
as the IgM concentrations in the supernatants increased with the amount of antibody 
provided. This experiment was performed several times in biological replicates and 
different incubation times ranging from 24h to 120h, with similar results. Figure 4-c 
presents the representative results of IgM measurement after 72h and 96h, respectively.  
 
Additionally I examined the binding of the aBAFFR that was commercially purified from 
9B9 hybridomas (102) by BIOTEM through Western blot. The BAFFR contains 175 amino 
acids, has a size of about 19kDa and can be found in many glycosylated forms. Using the 
aBAFFR antibody as detection antibody for the blot, I could identify a specific band in 
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lysates of C57BL/6 splenocytes as well as of the B1 cell line BCL-1 that was used as control  
(Fig.4-b). 
 
 
  
Exclusion of endotoxin side effects: 
 
Because endotoxin has been shown to stimulate IgM secretion, a potential contamination 
of the antibody with LPS needed to be excluded. Endotoxin measurements in the aBAFFR 
antibody aliquots showed only negligible values of 0,00368 ng per µg of protein in one 
aliquot and 0,000234 ng per µg of protein in the second aliquot. The control antibody 
contained only 0,000117ng endotoxin per µg of protein. To further confirm that the 
increased IgM production was really due to specific BAFFR blocking and not a result of 
endotoxin contamination I repeated the same assay that is presented in Fig.4-a in the 
presence of the LPS-neutralizing agent Polymyxin B (PMB). 
 
PMB is used to absorb LPS in reagents that are used for immunological experiments, as 
LPS can induce strong immune reactions, which can interfere with the experimental 
results. Consistent with the low levels of endotoxin in the antibody preparations, addition 
of PMB did not decrease the IgM production induced by BAFFR-neutralization after 48h 
(Fig.4-d). This supports that the effect we see in the increase of IgM secretion is obtained 
by interaction of the receptor with the blocking aBAFFR antibody. 
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Fig. 4: a) IgM secretion after aBAFFR treatment of mouse peritoneal cells. After 48h incubation 
supernatants of aBAFFR treated cells, in both concentrations 20µg/ml (50,3ng/ml) and 40µg/ml 
(88,3ng/ml), show significantly increased IgM concentrations compared to untreated (24,7ng/ml) 
and 20µg/ml (24,6ng/ml) or 40µg/ml (25,8ng/ml) control antibody treated cells. Data are 
presented as mean ± SEM of 3 replicates; * indicates p<0,05 versus untreated and control 
antibody. Data are representative of at least two independent experiments. b) Western blot for 
splenocyte- and BCL-1 cell-lysate. Specific binding of aBAFFR Ab to proteins with a molecular 
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weight of the BAFFR (19kDA) is displayed. c) IgM secretion after aBAFFR treatment of mouse 
peritoneal cells.  After 72h aBAFFR treated cells, in both concentrations 20µg/ml (81,8ng/ml) and 
40µg/ml (88,9ng/ml), show increased IgM concentrations compared to untreated (47,8ng/ml) and 
20µg/ml (38,9ng/ml) or 40µg/ml (42,3ng/ml) control antibody treated cells. After 96h aBAFFR 
treated cells, in both concentrations 20µg/ml (113,3ng/ml) and 40µg/ml (167,3ng/ml), show 
significantly increased IgM concentrations compared to untreated (71,2ng/ml) and 20µg/ml 
(54,9ng/ml) or 40µg/ml (55,9ng/ml) control antibody treated cells. Data are presented as mean ± 
SEM of 2 replicates. d) Exclusion of endotoxin contamination. IgM titers in supernatants of 
aBAFFR treated cells are higher than those of the control antibody treated cells. PMB at different 
concentrations did not neutralize the effect. Data are presented as mean ± SEM of 3 replicates, 
*** indicates p<0,0001. Data are representative of at least two independent experiments. 
 
 
 
aBAFFR treatment proliferation assay 
 
To test whether the increase in IgM after aBAFFR treatment might be due to increased 
proliferation of B1 cells during the treatment I performed a proliferation assay. I cultured 
total peritoneal cells for 48h alone or in the presence of aBAFFR antibody or control 
antibody. The percentages of the major cell populations present in the different wells 
were then analyzed by FACS staining. 
The total number of cells acquired at the end of the experiment was not different 
between the conditions. After gating on living cells, there was no difference in 
percentages between B1, B2, macrophages and T cells with and without treatment with 
aBAFFR antibody (Table 1). This suggests that blocking of the receptor does not lead to 
proliferation of B1 or B2 cells and therefore proliferation cannot explain the increase in 
IgM levels. 
 
% of viable cells ±SD untreated control antibody anti-BAFFR antibody 
B1 cells 55 ±0,28 53,63 ±0,21 56,37 ±1,10 
B2 cells 12,43 ±0,47 10,50 ±0,26 10,08 ±0,32 
Macrophages 15 ±0,71 15,17 ±1,11 14,4 ±1,61 
T cells 12,8 ±0,99 11,9 ±0,72 11,93 ±0,47 
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Table 1: Percentages of different cell populations present after antibody treatment in vitro. 
Gated on viable cells the percentages of B1, B2, macrophages and T cells stay unchanged after 
treatment with aBAFFR, compared to control antibody and untreated cells.  Data are 
representative of at least two independent experiments. 
 
 
 
aBAFFR effects equal aBAFF treatment effect in peritoneal cells 
 
Treatment of total peritoneal cells with aBAFFR antibody resulted in an increase in IgM 
secretion. To support this finding, I decided to interfere with the BAFF-BAFFR signaling by 
using an antibody against BAFF, the only ligand for the BAFFR. The hamster-anti- BAFF 
monoclonal antibody used was provided by GSK as part of collaboration to investigate its 
role in atherosclerosis. 
Again peritoneal cells were isolated from C57BL/6 mice and cultured in the presence of  
aBAFFR or aBAFF antibodies, respectively. Cells were incubated for 72h and supernatants 
analyzed for the presence of IgM. Both blocking the receptor and neutralizing its ligand 
with aBAFF resulted in increased spontaneous IgM secretion (Fig.5). 
 
 
 
Fig. 5: Comparison of the aBAFFR and aBAFF effect on IgM production in peritoneal cells. Both 
aBAFFR (210,2ng/ml) and aBAFF (240,2ng/ml) treated peritoneal cells showed significantly 
increased IgM secretion after 72h compared to untreated cells (98,2ng/ml). The difference in IgM 
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secretion between aBAFFR and aBAFF treated cells was not significant. Data are presented as 
mean ± SEM of 4 replicates, * indicates p<0,05, ** indicates p<0,005. 
 
 
 
BAFFR expression on cells in the peritoneum 
 
The expression of BAFFR on the surface of peritoneal cells was investigated. Previous 
publications reported that B cells and activated T cells, in contrast to non-activated T 
cells, express BAFFR. (90-92, 111) There were no indications for macrophages expressing 
BAFFR in the literature. For this purpose I examined the surface expression on peritoneal 
cells by flow cytometry using a FITC-labeled aBAFFR antibody. 
Total peritoneal cells were isolated from C57BL/6 mice, and cells were stained with 
antibodies against B220, which is a B cell marker, CD11b to distinguish between B1 and 
B2 cells and macrophages, CD5 to distinguish between B2 cells and T cells , and BAFFR to 
examine receptor expression on the cell surface. I could confirm the expression of the 
BAFFR on B cells (B1a, B1b and B2), while T cells were negative for it. Surprisingly, 
macrophages also exhibited positive BAFFR staining indicating surface expression of the 
receptor on peritoneal macrophages (Fig.6-a). To confirm this finding, I purified each 
peritoneal cell population by FACSorting to obtain B1 cells, macrophages and T cells. The 
purity of each population was greater than 80%. Isolated cells were then stained with the 
FITC-conjugated aBAFFR antibody to study BAFFR expression. As indicated in Fig 6-b, 
positive BAFFR staining was found on B1 cells as well as macrophages, whereas T cells 
were negative as seen before. 
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Fig. 6: FACS-Staining for BAFFR on peritoneal cells. a) Gated on viable cells, individual cell 
populations are shown based on CD11b and CD5 expression. The histogram plot on the right 
shows BAFFR expression intensity for each cell population. B1a, B1b, B2 and macrophages are 
positive for BAFFR staining, while T cells appear negative. b) After FACSorting following purities 
were achieved: B1 cells – 82,9%, macrophages – 89,8%, T cells – 82,0%. B1 cells were slightly 
contaminated with T cells and some B1 cells could be observed in the macrophages enrichment. 
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The T cell pool contained few B2 cells. Further staining for BAFFR showed that T cells do not 
express the BAFFR and therefore show no positive signal in the FITC channel. B1 cells and 
macrophages both give a positive signal which indicates that they express the receptor. Data are 
representative of at least two independent experiments 
 
 
 
BAFFR Expression on RAW and BCL-1 cells  
 
After observing BAFFR expression on peritoneal macrophages, I additionally investigated 
its expression in the RAW macrophage cell line. I stained both RAW cells as well as BCL-1 
cells, which served as positive control. The obtained results indicated once more BAFFR 
expression on macrophages as signal was almost as strong as that obtained with BCL-1 
cells. Stained BCL-1 and RAW were compared to unstained cells (Fig.7).  
 
 
 
Fig. 7: FACS-Staining for BAFFR on RAW and BCL-1 cells. BCL-1 cells and RAW macrophages give a 
distinct positive signal, indicating express of the BAFFR. Negative controls were unstained cells of 
each cell line. 
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XBP-1 and Blimp-1 expression in peritoneal cells after aBAFFR 
treatment 
 
B-lymphocyte-induced maturation protein 1 (Blimp-1) has an essential role for antibody 
secretion by B2 and B1 cells, ex vivo and in vivo, and it is known to be involved in IgM 
secretion. Blimp-1 is necessary for full induction of IgH, J-chain, and X-box binding protein 
1 (XBP-1) mRNAs in B2 cells. B1 cells, like B2 cells, require Blimp-1 and Blimp-1–
dependent de-repression of XBP-1 to secrete Ig. (112, 113) 
I examined if the expression of these two genes in total peritoneal cells is changed 
following aBAFFR treatment, as IgM secretion is induced. Total peritoneal cells were 
incubated with aBAFFR or isotype control antibody for 4h, 24h and 48h. IgM titers were 
measured in the supernatants to confirm the increase in the supernatants of aBAFFR 
treated cells after 24h and 48h. Cells were lysed, mRNA isolated and a quantitative RT-
PCR was performed for XBP-1 and Blimp-1. Gene expression was normalized to Cyclic B. 
No difference in gene expression levels of the two target genes could be identified (Fig.8). 
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Fig. 8: RT-PCR for XBP-1 and Blimp-1 in aBAFFR treated peritoneal cells. IgM ELISA shows 
increase in IgM levels after 24h and 48h, when cells are treated with aBAFFR antibody (left). qPCR 
shows no difference in gene expression of XBP-1 and Blimp-1 (right). 
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Serum BAFF levels in LDLR-/- mice on ND or HFD 
 
Previous work in our group showed that LDLR-/- mice that were fed a high fat diet for 12 
weeks (HFD, 0.2% Cholesterol, 21% milk fat; TD88137 Sniff) show dramatically increased 
IgM titers compared to mice fed a regular chow diet (ND). In the foregone data I 
presented how the BAFF-BAFFR system could modulate IgM secretion. Therefore, I 
wanted to investigate if there may be a difference in serum BAFF levels between the 
LDLR-/- mice on HFD and those on ND. BAFF levels in serum were measured using a 
commercial ELISA. The results of the BAFF measurements show that there is no difference 
in serum BAFF concentrations between mice on ND and mice on HFD (Fig.9). 
 
 
 
Fig. 9: Serum BAFF titers of LDL-/- mice after 12 weeks on ND or HFD. Sera of 11 mice per group 
were analyzed and no significant differences in BAFF levels were found between the two groups. 
In the ND mice the average serum BAFF concentration was 4663 pg/ml and in HFD mice the 
average was 5209/ml. Each data points indicate the levels obtained from individual mice, and the 
horizontal line indicates mean value for each group; n.s. indicates p>0,05 using unpaired t-test.  
 
 
 
aBAFFR treatment of sorted peritoneal B1 cells : 
 
The observed effects of aBAFFR on IgM secretion may come from direct interaction of the 
aBAFFR antibody with the BAFFR on B cells, thereby stimulating more secretion, or 
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through blockage of the receptor resulting in increased availability of BAFF ligand to bind 
to other receptors, such as TACI, leading to more IgM secretion. I examined this by either 
only blocking the receptor on sorted B cells or by additionally providing cells with excess 
of recombinant BAFF protein. If only blocking of the receptor on B1 cells was sufficient, 
increased IgM titers in the supernatants of cells treated with the aBAFFR antibody  should 
be observed. If binding to TACI was involved IgM levels are expected to increase, when 
excess BAFF protein is present independent of BAFFR blockage, as the ligand would have 
the capacity to bind to TACI. 
For this purpose total peritoneal cells were isolated from C57BL/6 mice, and B1 cells, 
macrophages, and T cells were sorted subsequently. Purified B1 cells were treated 
accordingly in vitro for 72h. Recombinant BAFF protein did not stimulate IgM secretion, 
whereas blocking of the BAFFR increases IgM titers significantly independent of presence 
or absence of recombinant BAFF protein.  
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Fig. 10: Antibody treatment of sorted peritoneal B1 cells. a) Fow cytometry plots of sorted cells 
indicating purities of cell populations obtained. B1 cells were 92% pure, macrophages 81% and 
were contaminated mainly with B1 cells, T cells were 98% pure. b) IgM levels after B1 cells were 
treated with different antibodies. Increase in IgM could be shown when cells were incubated with 
different concentrations of aBAFFR antibody (18,3ng/ml and 17,7ng/ml) and also when cells were 
pre-treated with aBAFFR and then provided with recombinant BAFF protein (21,9ng/ml) 
compared to untreated cells (9,0ng/ml) and control Ab (10,9ng/ml and 13,0ng/ml) treated cells. 
Recombinant BAFF (7,88ng/ml) alone did not cause change in IgM secretion. Data are presented 
as mean ± SEM of 3 replicates, * indicates p<0,05, ** indicates p<0,005, *** indicates p<0,0001. 
Data are representative of at least two independent experiments. 
 
 
 
Macrophages stimulate IgM secretion in primary sorted B cells 
 
Following peritoneal cell sorting (see purity Fig. 10-a) I also investigated whether the 
presence of other cell types together with B1 cells in culture modulates IgM secretion 
independently of the BAFFR signaling. Therefore, I combined the major cell types present 
in the peritoneal cavity to see if they modulate the IgM secretion capacity of B1 cells. 
Sorted B1 cells were cultured either alone or in the presence of macrophages or T cells or 
both. Interestingly, the presence of macrophages resulted in an 18-fold increase of IgM 
secretion during 72h compared to B1 cells alone. The presence of T cells on the other 
hand had no effect. When all three populations were present B1 cells produced more IgM 
compared to B1 cells alone, but only half of the concentrations that were produced when 
B1 cells and macrophages were in culture in the absence of T cells (Fig. 11). 
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Fig. 11: IgM titers in co-cultures of primary sorted cells. In the supernatants where only B1 cells 
are present the mean IgM concentration found is 9,3ng/ml, when macrophages are present it 
increases to 179,4ng/ml, when T cells are present it is 18,2ng/ml and when all three populations 
are together it is 887ng/ml. Data are presented as mean ± SEM of 3 replicates, * indicates p<0,05, 
** indicates p<0,005.  
 
 
 
Cell contact mediated stimulation of IgM secretion by macrophages 
 
Taking the above mentioned results into consideration the question arose, whether the 
potential of macrophages to stimulate B1 cells to secrete IgM was dependent on cell 
contact or on the secretion of soluble factors, which then interact with B cells. To test this 
I used a transwell culture system in which the two cell populations are separated by a 
membrane allowing only small molecules like cytokines in medium to pass (Fig. 12). 
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Fig. 12: Schematic representation of the transwell-system. B cells were placed in the lower well 
and macrophages in the 2nd well on top of the membrane. Exchange of soluble factors is possible 
but cell contact of the two cell types is not. 
 
Sorted B1 cells (purity Fig. 10-a) were placed in the lower part of the transwell-plate and 
macrophages were placed in the upper well. In parallel experiments B1 cells were directly 
co-cultured with two different concentrations of macrophages. When macrophages were 
directly present in the B1 cell culture, IgM production was strongly induced and 
dependent on the number of macrophages. In contrast, supernatants obtained from the 
transwell assay did not show an increase in IgM production compared to B1 cells alone. 
These data suggests that direct cell-cell contact is required for the stimulation of IgM 
secretion by B1 cells through macrophages. (Fig. 13) 
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Fig. 13: IgM secretion in co-culture and transwell assay of primary sorted B1 cells and 
macrophages. Strong increase in IgM titers can be seen when B1 cells are cultured with Mph 
(179,4ng/ml) and the titers decrease with the decrease in macrophages cell numbers present 
(101,2ng/ml). The transwell (TW, 25,8ng/ml) supernatant measurement shows no significant 
difference compared to B1 cells alone (9,3ng/ml) in culture. Data are presented as mean ± SEM of 
3 replicates, *** indicates p<0,0001. Data are representative of at least two independent 
experiments. 
 
 
 
RAW cells induce cell contact mediated IgM secretion in BCL-1 cells  
 
To strengthen the finding of the capacity of macrophages to stimulate IgM secretion by 
B1 cells, I did similar assays using BCL-1 cells, a B cell lymphoma cell line and RAW 
macrophages. In the experimental approach, I evaluated whether increasing numbers of 
RAW macrophages increase IgM secretion by BCL-1 cells. For this, 50,000 BCL-1 cells per 
well were cultured for 10h with increasing numbers of RAW macrophages (between 0 and 
150,000 cells per well). Indeed, increased numbers of RAW cells resulted in increased 
production of IgM by BCL-1 cells, which strongly supports the capacity of macrophages to 
up-regulate IgM secretion by B1 cells (Fig. 14-a).  
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Moreover, I further validated the importance of cell-cell contact for this activity of 
macrophages using these two cell lines. Again I used the transwell system to test this. 
BCL-1 cells were plated either alone, together with RAW cells, or separated from RAW 
cells by a membrane, and incubated for 18h in the transwell culture and supernatants 
were analyzed for IgM secretion. Consistent with the results obtained with primary cells, 
the results using RAW cells and BCL-1 cells demonstrate that cell-cell contact is required, 
as only when BCL-1 cells and RAW cells were cultured together an increase in IgM 
production was observed (Fig. 14-b). 
 
 
 
 
Fig. 14: IgM secretion in BCL-1 and RAW co-cultures. a) BCL-1 cells cultured with different 
numbers of RAW macrophages. The graph shows IgM levels in supernatants of cultures with a 
fixed BCL-1 cell number of 50,000 cells per well and increasing RAW cell numbers ranging from 0 
to 150,000 cells per well. IgM titers increased with numbers of RAW cells. Data are presented as 
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mean ± SEM of 2 replicates. Data are representative of at least two independent experiments. b) 
Transwell assay with BCL-1 and RAW cells. BCL-1 cells and RAW cells were plated in transwell 
assays, separated by a membrane, or cultured in regular 96-well plates. BCL-1 cells (33,1ng/ml) 
and BCL-1 /RAW transwell supernatants (30,9ng/ml) were found to have equal IgM titers while in 
the regular BCL-1 /RAW co-culture titers were again significantly increased (51,9ng/ml) compared 
to BCL-1 cells alone or BCL-1 cells cultured in the transwell system. Data are presented as mean ± 
SEM of 3 replicates, * indicates p<0,05. Data are representative of at least two independent 
experiments. 
 
 
 
IgM stimulation capacity of macrophages from LDLR-/- mice on ND 
or HFD 
 
It has been shown that atherosclerotic mice on a high cholesterol diet have higher IgM 
titers. Thus, I hypothesized that this could be due to an increased capacity of 
macrophages from cholesterol-fed mice to stimulate IgM secretion of B1 cells. To test this 
I fed one group of LDLR-/- mice a HFD for 12 weeks. The other group received a ND. 
Following sacrifice, macrophages were isolated from the two groups of mice by 
FACSorting of peritoneal cells obtained by lavage. In parallel, B1 cells were obtained from 
the peritoneal cavities of naïve C57BL/6 mice by FACSsorting (sorting purity Fig. 15-a). B1 
cells were then co-cultured with either macrophages obtained from mice on ND or HFD, 
respectively. After 72h IgM levels in supernatants were assessed by ELISA. Both types of 
macrophages stimulated B1 cells to produce IgM antibodies to a similar extent. Thus, the 
increase of IgM in LDLR-/- mice on a HFD is not due to a different stimulation capacity by 
macrophages (Fig. 15-b). 
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Fig. 15: IgM secretion in B1 cell co-culture with macrophages from mice on HFD and ND. a) Flow 
cytometry plots for the purity of sorted cell populations. The purity of the B1 cells obtained from a 
C57BL/6 mouse was 93%. Macrophages from mice on HFD had a purity of 90% and those from 
mice on ND were 91% pure. b) Comparing the IgM secretion stimulation capacity of macrophages 
obtained from LDLR-/- mice on ND and HFD. After 72h both ND (73,5ng/ml) and HFD (65,6ng/ml) 
macrophages induce IgM secretion of B1 cells compared to B1 cells (8,5ng/ml) cultured alone. 
There was no significant difference between the macrophages on different diets. Data are 
presented as mean ± SEM of 3 replicates, ** indicates p<0,005. 
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aBAFFR treatment of B1 cells in presence of macrophage and T cells 
 
Because the effect of the BAFFR blocking on IgM production by sorted B1 cells was less 
robust compared to the effect when total peritoneal cells were used, I wanted to examine 
whether aBAFFR treatment affects IgM secretion in the presence of other cell types. B1 
cells, T cells and macrophages were isolated from the peritoneal cavities of C57BL/6 mice 
by FACSorting (purity of the populations Fig. 10-a), and cultured in different combinations 
with other cells. In addition the effect of the aBAFFR antibody on IgM secretion under 
these specific experimental conditions was evaluated. 
Unfortunately, I only succeeded once in performing this experiment and additional repeat 
experiments would be needed. However, the preliminary results suggest that in the 
presence of macrophages IgM secretion of B1 cells is up regulated, but when T cells are 
added to this co-culture the increased IgM production is reduced. T cells alone have no 
effect on IgM secretion by B1 cells. In presence of aBAFFR antibody, the increased 
production of IgM antibodies induced by macrophages is reduced. In contrast, negative 
effect of T cells in this culture system is reversed by aBAFFR antibody. Thus, this suggests 
that blockage of the BAFFR decreases the capacity of macrophages to stimulate IgM 
secretion. T cells seem to suppress IgM production of B1 cells in presence of macrophages 
and addition of aBAFFR removes this suppression. (Fig. 16) 
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Fig. 16: aBAFFR treatment of co-culture of B1 cells with macrophages and T cells. Macrophages 
increase IgM secretion but in presence of aBAFFR the titers decrease. When macrophages and T 
cells are present the titers are decreased compared to only presence of macrophages, but when 
aBAFFR is added the titers increase again to the levels achieved when only B1 cells and 
macrophages are present. 
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DISCUSSION 
 
 
 
The dependence of B2 cell survival on the BAFF-BAFFR interaction is very well docu-
mented, while its role for B1 cells has not been described, except for the fact that it is not 
a determinant for B1 cell survival. As part of a mouse study performed in the laboratory, 
in which the role of BAFF neutralization in atherosclerosis is examined, the role of BAFF 
signaling on B1 cells functions needed to be studied and therefore was the focus of my 
diploma thesis.  
During the performance of the practical part I discovered two hitherto unrecognized 
pathways concerning IgM secretion by B1 cells. The first finding revealed the role of BAFF-
BAFFR signaling in peritoneal B cells on IgM secretion in vitro. In many independent 
assays I could show that neutralization of this signaling pathway with an anti -BAFFR 
blocking antibody resulted in increased IgM production. I confirmed specific binding of 
the antibody and also excluded any endotoxin side effects that could have acted on the 
IgM secretion as well.  
In attempts to understand how IgM secretion is promoted by blockage of the BAFFR, I 
first evaluated the possibility that an interaction of BAFF ligand with its other receptor 
TACI was involved. In such a scenario blockage of the BAFFR would allow more BAFF to 
bind TACI and this interaction may stimulate IgM production. However, my data do not 
support this, as adding excess recombinant BAFF protein to the cultures in vitro did not 
alter the IgM production. 
Importantly, I also could confirm this very interesting and novel effect of enhanced IgM 
production using an anti-BAFF antibody (GSK), which further verified that the observed 
effect is not dependent on TACI, as the ligand is neutralized by the antibody and therefore 
not able to interact. 
I could not unmask increased expression of genes associated with IgM secretion, such as 
XBP-1 and Blimp-1, in response to BAFFR neutralization.  In addition, I compared serum 
BAFF titers in LDLR-/- mice on HFD to those on ND, as they have increased serum IgM 
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titers. However, I did not observe a difference between mice on ND and HFD and 
therefore the increase in IgM in this case is unlikely linked to BAFF-BAFFR signaling.  
BAFFR blocking on B1 cells alone in culture slightly stimulates their IgM secretion but not 
to the extend seen in total peritoneal cell cultures. This raised the question if other cells 
are involved in the observed effect. Interestingly, my second discovery identified the fact 
that macrophages promote IgM secretion by B1 cells, independently of aBAFFR antibody 
treatment. Using primary sorted cells as well as in cell lines, I could further show that this 
stimulation in vitro is dependent on direct cell contact. This raised the question whether 
the spontaneous secretion of IgM in physiological conditions is maintained through 
macrophages and whether IgM secretion would be lower in their absence. Taking this 
into account I assumed there might be a difference in the s timulation capacity of 
macrophages coming from LDLR-/- mice on ND and HFD, as dramatically increased IgM 
titers are found in mice on a HFD. However, I could not identify differences in IgM 
antibody secretion by peritoneal B1 cells stimulated with peritoneal macrophages 
obtained from HFD or ND mice, respectively. 
With respect to the increased IgM secretion induced by aBAFFR antibody in total 
peritoneal cells, I could show that BAFFR blocking decreased IgM production in co-
cultures where both B1 cells and macrophages were present. When B1 cells, 
macrophages and T cells were present the titers were also lower than those when only B1 
and macrophages were present. However, when the BAFFR was blocked in presence of all 
three cell types the titers increased. This suggests that macrophages have the ability to 
stimulate IgM secretion and that this effect is down-regulated when the BAFFR is blocked. 
In the presence of T cells the stimulatory capacity of macrophages is down-regulated, but 
once the BAFFR is blocked this effect is reversed.  
Another very exciting finding I obtained is the potential expression of the BAFFR on 
macrophages. So far BAFFR expression on B cells has been described, but no indication 
for expression on macrophages exists in the literature. I could demonstrate expression of 
the BAFFR on primary peritoneal macrophages as well as RAW macrophages. Future 
studies will need to evaluate the functional role of BAFFR signaling in macrophages. 
BAFF-BAFFR signaling could activate macrophages to secrete stimuli or express surface 
molecules that have the capacity to interact with B cells. In addition, there is evidence 
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that endothelial cells express BAFF therefore one could hypothesize that 
monocytes/macrophages can interact with endothelial cells in a BAFF-BAFFR dependent 
manner. 
The finding described above indicate a beneficial role of BAFF-BAFFR neutralization in 
atherosclerosis as it could lead to the depletion of proatherogenic B2 cells but also an 
increased secretion of atheroprotective IgM by B1 cells thereby resulting in less 
atherogenesis. 
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MATERIALS AND METHODS 
 
 
 
IgM Enzyme-linked immunosorbent assay (ELISA) 
 
Buffers and Solutions: 
 PBS (pH 7.4, 1l): 
1,31g NaH2PO4 
5,75g NA2HPO4 
8,765g NaCl 
 
 PBS-Tween (1l): 
1l PBS 
1ml Tween20 (50%) 
 
 10xTBS (pH 7.4): 
0,15M NaCl 
50mM Tris 
0,27mM EDTA 
0,02% Azide 
 
 Dilution and Blocking Buffer: 
TBS 
1%BSA (RIA grade, SIGMA) 
 
 Lumiphos (Lumigen, Inc.) 
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Antibodies: 
 Coating antibody: anti-mouse-IgM (µ-chain specific), developed in goat, affinity 
isolated antigen specific antibody, (SIGMA) 
 Isotype Control: mouse IgM, κ, concentration 0.5 mg/ml , (BIOLEGEND) 
 Secondary Antibody: anti-mouse-IgM (μ-chain specific)-Alkaline phosphatase, 
developed in goat, (ZYMAD) 
 
Procedure: 
96-well U-bottom Elisa plates were coated with 40µl/well coating anti-mouse IgM (µ-
chain specific) antibody, diluted to 5µg/ml in 1xPBS, and incubated over night at 4°C (or 
1h at RT). Plates were washed 3x with PBS (BIO-TEK plate washer) and wells blocked with 
80µl/well BSA/TBS for at least 30min at RT. After washing plates with PBS-Tween, 30µl of 
samples and standards (isotype control: from 50 - 0,7812ng/ml) diluted in BSA/TBS were 
applied always in technical triplicates and incubated for 2h at RT (or o/n at 4°C). Plates 
were washed 3x with PBS-Tween and 40µl of secondary antibody, diluted 1:20 000 in 
BSA/TBS was added to each well for a 1h incubation at RT. Thereafter, plates were 
washed 3x with TBS, and 25µl of Lumiphos (diluted 1:3 in H20) per well were applied for 
60min at RT in darkness. Relative light units were measured with a Biotek Synergy 2 ELISA 
reader and analyzed with Microsoft Office Excel 2007, and significance was tested with 
GraphPadPrism 5.04 (GraphPad Software).  
 
 
BAFF-ELISA: 
For BAFF titer measurements in the sera of mice the Quantikine mouse 
BAFF/BLyS/TNFSF13B Immunoassay (R&D Systems) was used. LDLR-/- mouse serum 
samples were diluted 1:6 in the buffer provided in the kit and measured in technical 
duplicates. In total the titers were measured in sera of 11 mice. 
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Western Blot: 
 
Buffers and Solutions: 
 1xTBS-T: 
100ml 10xTBS 
2ml Tween20 
 
 10x TBS: 
12,1g Tris 
87,6g NaCl 
pH 7,5 
 
 4x Lower Buffer: 
1,5M Tris Hcl 
0,4% SDS 
pH 8,8 (HCl) 
 
 4x Upper Buffer: 
0,5M Tris HCl 
0,4% SDS 
pH 6,8 
 
 10x Running Buffer (1L): 
144g Glycin 
30g Tris 
10g SDS 
dH2O (pH 8,3) 
 
 10x Transfer Buffer: 
250mM Tris 
1,92M Glycine 
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 1xTransfer Buffer (1L): 
100ml 10xTransfer Buffer 
100ml MeOH 
dH20 
 
 1xTBS-T: 
100ml 10xTBS 
2ml Tween20 
 
 Lower Gel 1,5mm: 
3ml 30% Acrylamide 
4,5ml H2O 
2,5ml 4x Lower Buffer 
100µl Ammonium Persulfate 
8µl TEMED 
 
 Upper Gel 1,5 mm: 
0,6ml 30% Acrylamide 
0,8ml 4x Upper Buffer 
1,8ml dH2O 
32µl Ammonium Persulfate 
2,5µl TEMED 
 
 2x Laemli Lysis Buffer: 
4% SDS 
20% glycerol 
10% 2-mercaptoethanol 
0,004% bromphenol blue 
0,125M Tris HCL 
 
 ECL Plus Western Blotting Detection System (GE Healthcare) 
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Sample preparation: 
Splenocytes from C57Bl/6 mice and BCL-1 cells were lysed in Laemmli lysis buffer, heated 
at 100°C and vortexed well before loading on the gel. 
 
Procedure:  
The lower part of the gel was poured in gel cassette and covered with 1ml Isopropanol, 
which was removed by washing with H2O after gel polymerization. The upper part of the 
gel was poured on top of the lower gel and mounted with a slot comb, which was 
removed after polymerization. The cassette was placed in an electrode chamber filled 
with Running Buffer. 10µl of cell lysates were loaded on the gel. Proteins were separated 
in a run at 100V (~1h). After removal of the upper gel the lower part of the gel was 
transferred on a nitrocellulose membrane. The transfer was performed in a Bio-Rad 
Trans-Blot Semi-Dry System at 15V for 30min. Membranes were blocked with TBS-
T/3%BSA o/n at 4°C (or for 2h at RT). First, target specific antibodies and secondary 
detection antibodies were diluted in TBS-T/3%BSA, applied for 1h one after each other 
and in between membranes were washed 3 times with TBS-T for 10min. 1ml of ECL Plus 
solution was administered to the membranes for 5min before exposure. Pictures were 
taken and analyzed with ImageLab (BIO-RAD). 
 
 
FACS: 
 
Buffers and Solutions: 
 FACS- Buffer: 
PBS 
2% FBS 
 
Staining antibodies: 
 aCD16/32 CD16/32 (FCGR3, IGFR3, FCGR2, FC Receptor Block) Rat IgG2a, λ, mouse 
CD16/CD32, (used 1:200), (eBioscience) 
 aCD5 PE, Rat IgG2a, κ, mouse CD5, (used 1:100), (eBioscience) 
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 aCD11b APC Rat IgG2b, κ, mouse CD11b, (used 1:800), (eBioscience) 
 aCD45R(B220) PerCP-Cy5.5, Rat IgG2a, κ, CD45, (used 1:800), (eBioscience) 
 CD268 (BAFF Receptor) FITC, Rat IgG1, κ, mouse CD268, (used 1:800), (eBioscience) 
 
All antibodies were diluted in FACS-Buffer. 
 
Cell Sorting: 
Total peritoneal cells were isolated from C57BL/6 (or LDLR -/-) mice by peritoneal lavage 
(see animal handling) and blocked with 800µl mouse anti-CD16/32 for 20min on ice. After 
washing 3x with FACS-Buffer, cells were resuspended in 800µl antibody mix (CD5-PE, 
B220-PerCP Cy5.5 and CD11b-APC) and incubated for further 20min at 4°C in darkness. 
Additionally, for each cell surface marker single stainings with antibodies labeled with a 
distinct fluorescent dye were prepared for laser compensation. Afterwards cells were 
washed 3x with FACS-buffer and sorted with FACSAria (BD Biosciences) according to their 
cell surface marker expression. Purities of the populations were confirmed with 
FACSCalibur and FlowJo- Flow Cytometry Analysis Software (TreeStar). Subsequently, cells 
were used for BAFFR staining or cell culture experiments (see below). 
 
B1: B1a - B220+, CD11b+, CD5+ and B1b - B220+, CD11b+, CD5-;  
Macrophages: B220-, CD11bhigh, CD5-;  
T cells: B220-, CD11b-, CD5+;  
 
Staining for BAFFR expression on peritoneal cells:  
-Unsorted PEC: 500,000 isolated cells were blocked with 100µl aCD16/32 antibody for 
20min on ice and after washing 3x with FACS-Buffer  stained in 100µl antibody mix 
(BAFFR-FITC, CD5-PE, B220-PerCP Cy5.5 and CD11b-APC) for 20min on ice. Finally, cells 
were washed 3x with FACS-buffer. 
-Sorted PEC: approximately 50,000 B1 cells, macrophages and T cells obtained from cell 
sorting were incubated in 100µl aBAFFR-FITC antibody for 20min on ice and washed 3x 
with FACS-Buffer. 
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Flow cytometry was performed using a FACSCalibur machine (BD Biosciences) and data 
were analyzed using FlowJo- Flow Cytometry Analysis Software (TreeStar). 
 
Staining for BAFFR expression on RAW and BCL-1 cell line: 
Approximately 500,000 cells of each cell line were blocked with 100µl anti -CD16/32 
antibody (diluted 1:200) for 20min on ice. After washing 3x with FACS-buffer and pelleting 
for 5min at 1300 rpm, cells were resuspended in 100µl anti-BAFFR-FITC antibody (diluted 
1:800), incubated for 20min on ice, and washed 3x with FACS-buffer. Stained cells were 
analyzed on a FACSCalibur (BD Biosciences) instrument and data processed using FlowJo- 
Flow Cytometry Analysis Software (TreeStar). 
 
 
In vitro experiments: 
 
Media: 
 Dulbecco's Modified Eagle's Medium - DMEM (GIBCO) 
 RPMI - Roswell Park Memorial Institute (GIBCO) 
 Dulbecco's Phosphate-Buffered Saline D-PBS (SIGMA) 
 
Cell lines: 
 Mouse leukemic monocyte macrophage cell line - RAW 264.7: 
A mouse cell line derived from the ascites of a tumor induced in male BALB/c mice by 
intraperitoneal injection of Abselon Leukaemia Virus (A-MuLV). Cells are typically 
adherent and mainly used in metabolic, inflammation and apoptosis studies. RAW 264.7 
were cultured at 37°C in DMEM media containing 10% heat inactivated Fetal Bovine 
Serum (FBS), 1% Penicillin/Streptomycin, and 1% Glucose. For maintenance, cells were 
detached using a cell scraper (Fisher), pelleted for 5min at 1300rpm, and re-plated 1:4 in 
a fresh culture dish. 
 B cell Lymphoma 1 - BCL-1 : 
A mouse cell line established from a spontaneous lymphoma obtained from a female  
BALB/c mouse. This cell line is most likely of B1a origin and expresses CD5, surface IgM, 
 
 
58 
 
Mac-1, CD43 and low level of B220. Bcl-1 cells were cultured at 37°C in RPMI media 
containing 10%FBS, 1% Penicillin/Streptomycin, 1% Sodium Pyruvate, and 0,1% beta-
mercaptoethanol. Cells adhere lightly but can be detached easily by flushing the flask with 
media.  
 
Cell Counting: 
Cells were counted using a CASY® Technology Cell Counter from Roche Innovatis AG. 
 
Antibodies: 
 Anti-mouse BAFFR 9B9-Hybridoma antibody (by Rolink (102); antibody purification by 
BIOTEM) 
 Isotype matched control antibody: rat IgG2b 
 Recombinant mouse BAFF protein (R&D Systems) 
 Hamster Anti-mouse-BLyS/BAFF (GSK, HGS) 
 Anti-mouse CD40 (eBioscience) 
 
aBAFFR treatment of total peritoneal cells: 
Total peritoneal cells from a C57Bl/6 mouse were isolated, and 100,000 cells per well 
were placed in a 96-well plate in 200µl serum free DMEM media. Secretion of untreated 
cells was compared to that of cells treated with 20µg/ml and 40µg/ml of anti -BAFFR or 
control antibody. Each experimental condition was performed in biological triplicates, and 
cells were incubated for 48h, 72h or 96h at 37°C / 5% CO2. Cells were removed by 5min 
centrifugation at 1,300 rpm and supernatants were used for IgM titer measurement by 
ELISA.  
 
Exclusion of endotoxin side effects: 
50,000 peritoneal cells from C57BL/6 mice per well were plated in serum free DMEM 
media in a 96-well plate. PMB was added in different concentrations to the antibodies 
(10µg/ml, 20µg/ml, 30µg/ml) and incubated for 1h at 37°C. 20µg/ml and 40µg/ml of anti-
BAFFR or control antibody were added to the cells , and cultured at a final volume of 200µl 
per well for 48h at 37°C / 5% CO2. Supernatants were assayed for IgM. 
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Anti-BAFF treatment of total peritoneal cells: 
PEC were isolated from C57BL/6 mice, and 50,000 cells in 200µl serum free DMEM media 
per well were plated in 96-well cell culture plates. Three different conditions in biological 
quadruplicates were compared: untreated cells, cells treated with 40µg/ml anti -BAFFR, 
and cells treated with 10µg/ml anti-BAFF. Cells were incubated for 72h at 37°C / 5% 
CO2and then pelleted for 5min at 1,300 rpm to obtain cell free supernatant for further 
analyses. 
 
Anti-BAFFR treatment proliferation assay: 
PEC were isolated from C57BL/6 mice and 100,000 cells in 200µl serum free DMEM per 
well were plated in 96-well culture plates. Cells were treated with 40µg/ml aBAFFR, 
40µg/ml control antibody, or left untreated and incubated at 37°C / 5% CO2. After 48h the 
cells were counted, stained will specific antibodies for flow cytometry, and percentages of 
different cell populations of total living cells were quantified. 
 
Anti-BAFFR and BAFF treatment of sorted B1 cells: 
B1 cells were obtained by sorting of peritoneal cells of C57BL/6 mice. 50,000 B1 cells 
were plated in 96-well plates in 200µl per well serum free DMEM media. 20µg/ml and 
40µg/ml of anti-BAFFR or control antibody or 10ng/ml BAFF recombinant protein were 
added to the wells in triplicate cultures. In addition, cells were incubated with 40µg/ml 
anti-BAFFR and then 10ng/ml BAFF recombinant protein was added. Following 72h 
incubation at 37°C / 5% CO2 IgM titers were measured in the supernatants. 
 
Anti-BAFFR treatment of sorted peritoneal cells in co-culture: 
Cells obtained from cell sorting were co-cultured in different combinations. B1 cells alone, 
B1 cells and macrophages, B1 cells and T cells and B1, macrophages and T cells together. 
50,000 cells of each cell type was present per well in 200µl serum free DMEM media. 
Each combination was either untreated or treated with 20µg/ml or 40µg/ml anti-BAFFR 
or control antibody. Cells were incubated for 6 days at 37°C / 5% CO2and the IgM titers in 
the supernatants were measured by IgM ELISA. 
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Titration of BCL-1 and RAW cells: 
Different numbers of BCL-1 cells and RAW macrophages were co-cultured, starting from 0 
to 150,000 cells per well from each cell line at different combinations. Cells were cultured 
in 200µl serum free DMEM media for 10h at 37°C / 5% CO2. IgM was assayed by ELISA in 
cell supernatants.  
 
Transwell Experiment for sorted peritoneal cells: 
For the transwell experiments, HTS-Transwell 96-well plates with a 5.0µm Polycarbonate 
Membrane (CORNING) were used. 50,000 B1 cells were plated in the lower well and 
50,000 macrophages were added in the second well on top. Results were compared to B1 
cells cultured alone and B1 cells cultured in a 96-well cell culture plate together with 
50,000 and 25,000 macrophages in a total volume of 200µl serum free DMEM media. The 
cells were incubated for 72h at 37°C / 5% CO2 and IgM titers were measured in 
supernatants. 
 
Transwell experiment for BCL-1 and RAW cells: 
HTS-Transwell 96-well plates with a 5.0µm Polycarbonate Membrane (CORNING) were 
used. 50,000 BCL-1 cells were placed in the lower well and 50,000 RAW macrophages 
were added in the second well on top in a total of 200µl serum free DMEM media. Cells 
were incubated for 18h at 37°C / 5% CO2 and the IgM titers were measured in the 
supernatants. 
 
Comparing macrophage from ND vs. HFD LDLR-/- in terms of IgM stimulation: 
B1 cells were obtained by cell sorting of peritoneal cells  obtained from C57Bl/6 mice, and 
peritoneal macrophages were obtained from LDLR -/- mice that were either fed HFD  for 12 
weeks or remained on a ND. 50,000 of each cell type per well were plated in 200µl DMEM 
media in 96-well cell culture plates. Three different conditions in biological triplicates 
were compared: B1 cells alone, B1 cells cultured with macrophages from ND mice, and B1 
cells cultured with macrophages from HFD mice. Cells were incubated for 72h at 37°C / 
5% CO2 and the supernatants were used for determination of IgM by ELISA.  
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Mouse handling: 
 
Buffers and Solutions: 
 Hank's Buffered Salt Solution – HBSS 
 Erythrocyte Lysis Buffer (Hämolysebuffer - Morphisto Evolutionsforschungund 
Anwendung GmbH) 
 
Mouse strains: 
 C57BL/6 mice: 
This mouse strain is an inbred strain that is most often used in the laboratory, as it is very 
robust and easy to bread. 
 LDLR-/- mice (low density lipoprotein- receptor knock-out mice) on a C57BL/6 
background: 
This mouse strain is a generally accepted animal model for the examination of 
hyperlipidemia and atherosclerosis. By feeding mice a cholesterol-rich diet, cholesterol 
levels are increased in the serum due to the lack of LDL receptors, and consequently the 
formation of atherosclerotic plaques is promoted. Therefore, this model is appropriate to 
follow the progression/regression of atherosclerotic plaques. 
 
Peritoneal Lavage: 
C57BL/6 mice were sacrificed by cervical dislocation. After sterilization with 70% Ethanol 
a small incision in the abdominal skin of the mouse was made using one set of forceps 
and scissors to access the peritoneal cavity. Per mouse 10ml of HBSS was injected in the 
lower abdominal region, to avoid organ puncture, using sterile 10ml syringes. Peritoneal 
cells were obtained by lavage and aspirated using a fresh 10ml syrine. Cells were 
recovered by 5min centrifugation at 1,300 rpm. 
 
Splenocyte isolation: 
The spleens of C57BL/6 mice were isolated with a pair of forceps and scissors and single 
cell suspensions were made by passing the tissue through a 100µm nylon cell strainer 
(Fisher Scientific). Erythrocytes were lysed by adding 1ml of red blood cell lysis buffer for 
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2min incubation at RT. To stop the reaction 10ml of ice cold PBS were added and cells 
pelleted for 5min at 1,300 rpm. 
 
 
RNA-Extraction: 
Peritoneal cells from the anti-BAFFR treatment experiment were lysed in RNA-Lysis Buffer 
and then RNA was isolated using the peqGOLD total RNA isolation kit (PEQLAB). The 
obtained RNA was diluted 1:10 in RNase free water before it was used to generate cDNA . 
 
 
Preparation of cDNA: 
cDNA was synthesized using high capacity cDNA RT kit (Applied Biosystems). First a 
master-mix was prepared, containing buffer, dNTPs, Oligos and H20. Afterwards RNA 
obtained from the RNA isolation was added and Reverse Transcriptase was applied. 
 
 1x Reverse Transcription 
1µl Buffer 
0,4µl dNTPs 
1µl Oligos 
0,5µl Reverse Transcriptase 
2,1µl H20 
5µl RNA 
 
Program: 
Cycles:  1. 25°C for 25min 
   2. 37°C for 120min 
   3. 85°C for 5sec 
   4. 4°C unlimited 
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RT-PCR: 
For the identification of expression levels of XBP-1 and Blimp-1, IQ Syper-Green Supermix 
(BIORAD) was used. The PCR was carried out in the BIORAD Thermal Cycler C1000 (CFX96 
Real Time System). 
 
 1x PCR: 
5µl Buffer (Syber Green)  
0,5µl Primermix (Forward: Reverse = 1:1) 
4,5µl cDNA (1:10) 
 
Sequences and primers: 
 XBP-1: (5′-A G C A C T C A G A C T A T G T G C A C C TCT -3′, 5′-T C C A G A A T G C C C A 
A A A G G A T A T C -3′) 
 Blimp-1: (5′-A G T A G T T G A A T GGG A G C -3′,  5′-C A A T G C T T G T C T A G T G T C 
-3′) 
 
Program:  
 1 cycle 50°C (2:00min);  
 1 cycle 94°C (10:00min);  
 40 cycles 95°C (0:15min) – 60°C (0:15min) – 72°C (0:45min) 
 1 cycle 95°C (0:15min) – 60°C (0:15min) – 95°C (0:15min) 
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